Articles related to Pulmonology

The median time to recovery in a group of 1,800 vaccinated and unvaccinated adults (median age: 48 years) was essentially the same whether the patients received ivermectin or placebo: 12 and 13 days, respectively. Death rate was slightly higher in the ivermectin group and rates of pneumonia and VTE were slightly higher in the placebo group.

This study of 2,500 adults receiving mechanical ventilation randomized 1/3 were assigned to an exigent saturation target pf 90%, 1/3 to a target of 94%, and 1/3 to a target of 98%. The median number of ventilator-free days was 20, 21, and 21 for the three target groups, respectively. In-hospital death by day 28 was 34.8%, 34.0%, and 33.2% for the three groups, respectively.

The study’s findings offer a novel perspective on norepinephrine reuptake inhibitors’ impact on “upper airway stability during sleep and are significant to guide future pharmacotherapy development for OSA,” according to the authors. Additionally, the findings offer individuals who are unable to tolerate modern therapies, such as continuous positive airway pressure (CPAP) equipment, wider alternatives when seeking therapy for OSA.

The oral suspension formulation was developed for patients who have difficulty swallowing the tablet form of the PDE5 inhibitor.

An observational analysis reviewed 54 studies and two medical record databases with data for 1.2 million individuals, to determine how many people experienced at least 1 of the 3 self-reported Long COVID symptom clusters 3 months after infection. The results indicate a Long COVID rate of 6.2%: 3.7% for ongoing respiratory problems, 3.2% for persistent fatigue with bodily pain or mood swings, and 2.2% for cognitive problems.

Palliative care (PC) can help reduce emergency department use, hospitalizations, and symptom burden across a spectrum of diseases. To assist clinicians in keeping their expertise current, the authors reviewed and summarized the top PC articles of 2020. The analysis included 28 PC intervention trials for heart failure, chronic obstructive pulmonary disease, and dementia.